These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

330 related articles for article (PubMed ID: 12211136)

  • 1. Amantadine and other antiglutamate agents: management of Parkinson's disease.
    Mov Disord; 2002; 17 Suppl 4():S13-22. PubMed ID: 12211136
    [No Abstract]   [Full Text] [Related]  

  • 2. Medications for Parkinson's disease.
    Whitney CM
    Neurologist; 2007 Nov; 13(6):387-8. PubMed ID: 18090719
    [No Abstract]   [Full Text] [Related]  

  • 3. Levodopa: management of Parkinson's disease.
    Mov Disord; 2002; 17 Suppl 4():S23-37. PubMed ID: 12211137
    [No Abstract]   [Full Text] [Related]  

  • 4. Renaissance of amantadine in the treatment of Parkinson's disease.
    Blanchet PJ; Metman LV; Chase TN
    Adv Neurol; 2003; 91():251-7. PubMed ID: 12442683
    [No Abstract]   [Full Text] [Related]  

  • 5. Is pathological gambling in Parkinson's disease reduced by amantadine?
    Lee JY; Kim HJ; Jeon BS
    Ann Neurol; 2011 Jan; 69(1):213-4; author reply 214-5. PubMed ID: 21280095
    [No Abstract]   [Full Text] [Related]  

  • 6. [Comparative study on Parkopan, Amantadine and L-dopa in the treatment of Parkinson's disease].
    Dzudza M; Dzudza D
    Med Arh; 1974; 28(4):407-15. PubMed ID: 4613968
    [No Abstract]   [Full Text] [Related]  

  • 7. Amantadine in Parkinson's disease: pro and contra.
    Greulich W; Fenger E
    J Neural Transm Suppl; 1995; 46():415-21. PubMed ID: 8821077
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Twenty-five years of amantadine therapy in Parkinson's disease.
    Danielczyk W
    J Neural Transm Suppl; 1995; 46():399-405. PubMed ID: 8821075
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Motor fluctuations in Parkinson's disease.
    Crabb L
    Prof Nurse; 2000 Jan; 15(4):273-7. PubMed ID: 10983145
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plasma amantadine concentrations in patients with Parkinson's disease.
    Nishikawa N; Nagai M; Moritoyo T; Yabe H; Nomoto M
    Parkinsonism Relat Disord; 2009 Jun; 15(5):351-3. PubMed ID: 18823813
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rimantadine in Parkinson's disease patients experiencing peripheral adverse effects from amantadine: report of a case series.
    Singer C; Papapetropoulos S; Gonzalez MA; Roberts EL; Lieberman A
    Mov Disord; 2005 Jul; 20(7):873-7. PubMed ID: 15809995
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transient amantadine-induced musical hallucinations in a patient with Parkinson's disease.
    Gondim Fde A; Costa HA; Taunay TC; de Oliveira GR; Ferreira JM; Rola FH
    Mov Disord; 2010 Jul; 25(10):1505-6. PubMed ID: 20629118
    [No Abstract]   [Full Text] [Related]  

  • 13. Combined treatment in Parkinson's disease.
    Wheatley D
    Practitioner; 1983 Mar; 227(1377):446-7. PubMed ID: 6889232
    [No Abstract]   [Full Text] [Related]  

  • 14. [Comparison between the effects of L-dopa, prodipine and amantadine on the serum and CSF amino acid levels in Parkinson's disease (author's transl)].
    Gründig E; Gerstenbrand F
    Wien Klin Wochenschr; 1980 Dec; 92(24):868-71. PubMed ID: 7222702
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current therapy of Parkinson's disease.
    Ajax T; Rodnitzky R; Dobson J
    Iowa Med; 1997 Jan; 87(1):27-9. PubMed ID: 9029838
    [No Abstract]   [Full Text] [Related]  

  • 16. Drug-induced delusions of parasitosis during treatment of Parkinson's disease.
    Swick BL; Walling HW
    J Am Acad Dermatol; 2005 Dec; 53(6):1086-7. PubMed ID: 16310077
    [No Abstract]   [Full Text] [Related]  

  • 17. A reticular rash.
    Salgado JC; Gutknecht DR
    Am J Med; 2006 Jul; 119(7):577-8. PubMed ID: 16828627
    [No Abstract]   [Full Text] [Related]  

  • 18. Parkinson's disease.
    Clarke C; Moore AP
    Clin Evid; 2002 Jun; (7):1208-20. PubMed ID: 12230738
    [No Abstract]   [Full Text] [Related]  

  • 19. Amantadine reduces the duration of levodopa-induced dyskinesia: a randomized, double-blind, placebo-controlled study.
    da Silva-Júnior FP; Braga-Neto P; Sueli Monte F; de Bruin VM
    Parkinsonism Relat Disord; 2005 Nov; 11(7):449-52. PubMed ID: 16154788
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Corneal endothelial dysfunction associated with amantadine toxicity.
    Chang KC; Kim MK; Wee WR; Lee JH
    Cornea; 2008 Dec; 27(10):1182-5. PubMed ID: 19034138
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.